130 related articles for article (PubMed ID: 32541479)
1. Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer: A protocol for systematic review and meta-analysis.
Zhang L; Zheng CY; Cao JH; Luo SL
Medicine (Baltimore); 2020 Jun; 99(24):e20558. PubMed ID: 32541479
[TBL] [Abstract][Full Text] [Related]
2. Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer.
Maene C; Salihi RR; Van Nieuwenhuysen E; Han SN; Concin N; Vergote I
Int J Gynecol Cancer; 2021 Jun; 31(6):824-828. PubMed ID: 33858952
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer: A protocol for a systematic review of randomized controlled trial.
Han L; Wei ZX; Lv YF; Jiang AY
Medicine (Baltimore); 2019 Apr; 98(14):e15099. PubMed ID: 30946371
[TBL] [Abstract][Full Text] [Related]
4. Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Zhang Y; Pan D; Yang H; Huang J; He Z; Li H; Li D
Medicine (Baltimore); 2020 Nov; 99(45):e22950. PubMed ID: 33157935
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311).
Ishikawa M; Nakamura K; Shibata T; Tanaka K; Kitagawa R; Kobayashi H; Yaegashi N;
Jpn J Clin Oncol; 2018 Dec; 48(12):1096-1100. PubMed ID: 30295796
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis.
Pu CL; Li JZ; Fan WL
Medicine (Baltimore); 2020 May; 99(21):e20297. PubMed ID: 32481312
[TBL] [Abstract][Full Text] [Related]
7. Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.
Tian Q; Du P; Li S; Bai Z; Yang Y; Zeng J
Medicine (Baltimore); 2017 Nov; 96(45):e8389. PubMed ID: 29137021
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combined with chemotherapy for ovarian cancer: A protocol for systematic review and meta-analysis.
Liao T; Li L; Wang L
Medicine (Baltimore); 2021 Dec; 100(51):e28376. PubMed ID: 34941162
[TBL] [Abstract][Full Text] [Related]
9. A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.
He ZY; Li HY; Yan J; Li SJ; Li DC; Liang ZZ
Trials; 2022 Jul; 23(1):556. PubMed ID: 35804452
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis.
Qiu W; Fu Y; Dang Y; Cai B; Tuo S; Mao B; Lin R; Liu Q; Li Y
BMJ Open; 2022 Mar; 12(3):e053182. PubMed ID: 35296476
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
17. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Yap TA; Bessudo A; Hamilton E; Sachdev J; Patel MR; Rodon J; Evilevitch L; Duncan M; Guo W; Kumar S; Lu S; Dezube BJ; Gabrail N
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35332062
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Tanigawa T; Takeshima N; Ishikawa H; Nishio S; Usami T; Yamawaki T; Oishi T; Ihira K; Kato H; Goto M; Saito M; Taira Y; Yokoyama M; Shoji T; Kondo E; Mori A; Yokoi T; Iwasa-Inoue N; Hirashima Y; Nagasawa T; Takenaka M; Mikami M; Sugiyama T; Enomoto T
Gynecol Oncol; 2022 Jun; 165(3):413-419. PubMed ID: 35487773
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer.
Yasunaga M; Yahata H; Okugawa K; Shimokawa M; Maeda Y; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
Taiwan J Obstet Gynecol; 2022 Sep; 61(5):818-822. PubMed ID: 36088050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
